Download full-text PDF

Source
http://dx.doi.org/10.1016/j.therap.2022.12.009DOI Listing

Publication Analysis

Top Keywords

positive rechallenge
4
rechallenge hemophagocytic
4
hemophagocytic lymphohistiocytosis
4
lymphohistiocytosis patient
4
patient treated
4
treated isoniazide
4
isoniazide pembrolizumab
4
pembrolizumab carboplatine
4
carboplatine pemetrexed
4
positive
1

Similar Publications

Statin-induced liver injury has been widely described. However, cases of clinically significant liver injury are rare. We present a 56-year-old woman who developed atorvastatin-induced grade III acute liver injury with concurrent rhabdomyolysis that worsened after rechallenging, which highlighted the need for pharmacovigilance with statins.

View Article and Find Full Text PDF

Objectives: We aimed to assess the characteristics of adverse drug reactions (ADRs) collected in a university hospital.

Methods: A retrospective analysis of ADRs spontaneously reported in the Hospital Pharmacovigilance Program database (RutiRAM) over a 13-year period was conducted. The analysis included a description of ADRs [System Organ Class (SOC)] and their seriousness, the drugs involved [level 1 of the Anatomical Therapeutic Chemical (ATC) Classification System], drug-drug interactions, medication errors, drugs 'under additional monitoring', positive rechallenge, and the 'pharmacovigilance interest' of ADRs.

View Article and Find Full Text PDF

An 85-year-old man with recently diagnosed metastatic EGFR+ lung adenocarcinoma treated with osimertinib presented after 1 month of therapy in decompensated congestive heart failure along with atrial fibrillation, prolonged QTc and acute kidney injury. Osimertinib was held. His hemodynamic status was optimized, and he was started on cardioprotective medications (losartan and metoprolol succinate), and LVEF recovered.

View Article and Find Full Text PDF
Article Synopsis
  • * A case study of a 54-year-old Saudi woman with SLE revealed that after conventional medication failed, treatment with belimumab improved her condition, but later led to worsening symptoms, including severe hair loss.
  • * The subsequent administration of baricitinib after stopping belimumab showed significant improvement in her hair loss and arthritis symptoms, suggesting a need for focused research on specific outcomes in SLE treatment, particularly regarding baricitinib's effectiveness.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!